Post job

Competitor Summary. See how Atreca compares to its main competitors:

  • AbVitro has the most employees (350).
  • The oldest company is Mersana Therapeutics, founded in 2001.
Work at Atreca?
Share your experience

Atreca vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2011
4.0
Redwood City, CA2$1.4M130
Bird Rock Bio
2002
3.8
San Diego, CA1$5.0M3
2006
3.8
Emeryville, CA1$500,00050
2012
3.9
Boston, MA1$10.0M350
2001
4.0
Cambridge, MA1$40.5M169
2015
3.8
Redwood City, CA1$7.7M91
2010
4.4
Burlingame, CA2$4.9M39

Rate Atreca's competitiveness in the market.

Zippia waving zebra

Atreca salaries vs competitors

Compare Atreca salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Atreca
$90,011$43.27-

Compare Atreca job title salaries vs competitors

CompanyHighest salaryHourly salary
Atreca
$85,043$40.89
Mersana Therapeutics
$91,560$44.02
Eureka Therapeutics
$89,431$43.00
Apexigen
$88,016$42.32
Bolt Biotherapeutics
$86,644$41.66
Bird Rock Bio
$82,071$39.46
AbVitro
$81,988$39.42

Do you work at Atreca?

Is Atreca able to compete effectively with similar companies?

Atreca jobs

0

Atreca and similar companies CEOs

CEOBio
Anna Protopapas
Mersana Therapeutics

Ms. Anna Protopapas is a Chief Executive Officer at MERSANA THERAPEUTICS, INC. and is based in United States.

Paul A. Grayson
Bird Rock Bio

Paul Grayson is a Board of Directors at Bird Rock Bio Inc, Managing Director at AccessBioVentures, and Partner at Versant Ventures and is based in San Diego, California. He has worked as Board Member at Naviscan Inc; Managing Director at Sanderling Ventures; and Senior Vice President, Corporate Development at Aurora BioScience. Paul works or has worked as Board Member at ALEXION PHARMACEUTICALS, INC.; Investment Professional at Versant Ventures; and Board Member at Anaphore. He attended UCLA between 1984 and 1987, Paul Merage School of Business between 1989 and 1991, and University of California Irvine between 1989 and 1991.

Xiaodong Yang
Apexigen

Dr Randall C Schatzman Ph.D.
Bolt Biotherapeutics

Dr. Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

Atreca competitors FAQs

Search for jobs